CNS Response Provides Poster Review of rEEG-Guided Pharmacotherapy of Dually-Diagnosed Addiction Patients at the US Psychiatric and Mental Health Congress
November 04, 2008
The Poster Will Be Discussed During the Companyís Upcoming Conference Call Being Held
Friday, November 7, at 2:00 EST
Costa Mesa, Calif. - November 4, 2008 - CNS Response, Inc. (OTCBB: CNSO) reported
today the results of a study presented at the U.S. Psychiatric and Mental Health Congress
by Mark J. Schiller, M.D., Director of Medical Affairs for CNS Response and Assistant Clinical
Professor in Psychiatry at the University of California, San Francisco. The poster
presentation, titled "Referenced-EEG-Guided Pharmacotherapy of Dual-Diagnosis Patients,"
provided an analysis of a patient-controlled case series conducted to examine the use of
CNS Response rEEG® in dual-diagnosis addiction patients.
The 77 patients met the criteria for DSM-IV (Diagnostic and Statistical Manual), Axis l, non-
psychotic psychiatric illness, and DSM-IV, alcohol/drug abuse/dependence diagnoses. The
patients, whose ages ranged from 14 to 62, were detoxified for 21 days and then prescribed
medications based on an individualized rEEG-guided treatment. Patient treatment took place
in a variety of residential and outpatient settings, as per standard clinical practice.
Initially 65 patients in the 77-patient study were assigned a CGI-Severity rating (Clinical
Global Impressions Ratings) of markedly ill or severely ill, and 12 patients were rated ill to
moderately ill. After receiving six weeks of rEEG-guided treatment, 77 percent of the
markedly or severely ill patients were rated much improved to very much improved in a
CGI-Improvement scale analysis, while 11 of the 12 mildly to moderately ill patients were
rated much improved to very much improved. Very much improved is the highest
improvement rating in the CGI rating system. The overall rating at the end of the study
indicated that 79 percent of the 77 patients rated much improved to very much improved.
"The data from this study indicates that the success rate of rEEG-guided pharmacotherapy
of dual-diagnosis addiction patients (patients with behavioral problems that do not include
hallucination or delusional beliefs, and that are also drug or alcohol dependent) is consistent
with success rates demonstrated in studies of patients with affective and attention-deficit
disorders," said Dr. Schiller.
"It is clear from this study and prior research," continued Dr. Schiller, "that rEEG can
provide an objective, physiologic basis for psychiatric treatment and has the promise to
fundamentally improve the nature in which psychiatric medicine is prescribed. We look
forward to developing and pursuing further research with rEEG."
"With 79 percent of patients in the clinical series experiencing significant improvement, Dr.
Schillerís study supports the experience that a number of treatment centers using rEEG
have reported. As opposed to treatment approaches where one approach is hoped to fit all,
the advantages of applying personalized medication regimens based on an analysis of a
patientís brain physiology is not only intuitively appealing but appears to be corroborated,"
commented CNS Response Chief Executive Officer Len Brandt.
The full poster presentation and analysis of results are available at
www.cnsresponse.com/ddposterpresentation
CNS Response Chief Medical Officer, Daniel Hoffman, M.D., noted, "This poster reinforces
previous data indicating that rEEG-guided personalized medicine can significantly benefit
dually-diagnosed patients and corroborates the success of rEEG across a wide spectrum of
psychiatric conditions, including patients with disorders of varying complexity. It is
important to note that our colleague, Dr. Jim Greenblatt, recently completed a study of
another dual-diagnosis population of patients with eating disorders and co-occurring major
depression. According to Dr. Greenblatt, without personalized medicine biomarker guidance,
determining treatment would have been extremely challenging. I am proud that our
colleagues are providing such important advances to the healthcare industry."
During the company's November 7 conference call, management will be discussing rEEG-
guided treatment of dually-diagnosed patients and results of four additional posters recently
presented at the U.S. Psychiatric and Mental Health Congress.
About CNS Response
CNS Response is a life-sciences data company whose patented system provides treatment
guidance to psychiatrists and other physicians for patients with behavioral (mental or
addictive) disorders. This technology allows CNS Response to create and provide simple
reports ("rEEG® Reports") that specifically guide physicians to treatment strategies based
on the patient's own physiology.
rEEG® utilizes traditional electroencephalography (EEG) in conjunction with a normative
database and a proprietary clinical (symptomatic) database to identify the following: (1)
medication classes most likely to be needed; and (2) medications within these classes with
the most probable treatment potential for each patient. Reports are provided to physicians
in a relationship analogous to that of a reference laboratory. Prospective, retrospective and
field studies of treatment-resistant patients have reported treatment success of 70 percent
or greater in managed care, outpatient psychiatric and residential substance abuse clinical
settings.
In addition to providing analytical support to physicians, CNS Response is also an aid to
pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve
the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of
investigational drugs; (3) identify additional indications for psychiatric medications; (4)
provide insight into effective drug combinations; and (5) discover opportunities for decision
analytics and support. In addition to these applications, CNS Response continues to
investigate the use of rEEG analysis for development of proprietary pharmaceutical
opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking
statements made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth
in the Company's filings with the Securities and Exchange Commission. These risks and
uncertainties could cause actual results to differ materially from any forward-looking statements
made herein.
Contact:
Investor and Media Relations:
Marty Tullio
McCloud Communications LLC
949.553.9748
marty@mccloudcommunications.com
# # #
Back to News and Press